Contact
searchSearch
HMP Global
Login

Head & Neck Cancer Specialty Channel

Head & Neck Cancer
Specialty Channel
Emma Connolly, MB BCh BAO
Videos
Redefining “High Risk” for Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck
10/21/2025
Emma Connolly, MB, BCh, BAO
Emma Connolly, MB BCh BAO, discusses an analysis which identified a distinct high-risk subgroup of patients with cutaneous squamous cell carcinoma of the head and neck who had inferior disease-free survival following postoperative...
Emma Connolly, MB BCh BAO, discusses an analysis which identified a distinct high-risk subgroup of patients with cutaneous squamous cell carcinoma of the head and neck who had inferior disease-free survival following postoperative...
Emma Connolly, MB BCh BAO,...
10/21/2025
Oncology
News
Sequential Chemoradiotherapy Plus Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
08/19/2025
Stephanie Holland
According to results from a phase 3 trial, sequential chemoradiotherapy plus concurrent chemoradiotherapy was noninferior compared to induction chemoradiotherapy plus concurrent chemoradiotherapy among newly diagnosed patients with...
According to results from a phase 3 trial, sequential chemoradiotherapy plus concurrent chemoradiotherapy was noninferior compared to induction chemoradiotherapy plus concurrent chemoradiotherapy among newly diagnosed patients with...
According to results from a...
08/19/2025
Oncology
Danny Rischin, MD, Peter MacCallum Cancer Centre
Videos
Adjuvant Cemiplimab as New Standard of Care for Patients With High-Risk Cutaneous Squamous Cell Carcinoma
06/06/2025
Danny Rischin, MD
Danny Rischin, MD, discusses the results from the phase 3 C-POST trial evaluating adjuvant cemiplimab for patients with high-risk cutaneous squamous cell carcinoma.
Danny Rischin, MD, discusses the results from the phase 3 C-POST trial evaluating adjuvant cemiplimab for patients with high-risk cutaneous squamous cell carcinoma.
Danny Rischin, MD, discusses the...
06/06/2025
Oncology
Conference Coverage
Adjuvant Nivolumab Plus Chemoradiotherapy Decreases Chance of Recurrence in Patients With Head and Neck Cancer
06/01/2025
Emily Estrada
The addition of nivolumab to cisplatin-based chemoradiotherapy after surgery improved disease-free survival for patients with locoregionally advanced squamous cell carcinoma of the head and neck, according to findings from the NIVOPOSTOP...
The addition of nivolumab to cisplatin-based chemoradiotherapy after surgery improved disease-free survival for patients with locoregionally advanced squamous cell carcinoma of the head and neck, according to findings from the NIVOPOSTOP...
The addition of nivolumab to...
06/01/2025
Oncology
News
Neoadjuvant Nivolumab Plus Chemotherapy and Chemoradiation for Patients With HPV-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma
05/27/2025
Stephanie Holland
According to results from the phase 2 DEPEND trial, neoadjuvant nivolumab plus chemotherapy and response-stratified de-escalated chemoradiation demonstrated promise among patients with HPV-negative locally advanced head and neck squamous cell...
According to results from the phase 2 DEPEND trial, neoadjuvant nivolumab plus chemotherapy and response-stratified de-escalated chemoradiation demonstrated promise among patients with HPV-negative locally advanced head and neck squamous cell...
According to results from the...
05/27/2025
Oncology
News
First-Line Pembrolizumab With or Without Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
04/08/2025
Stephanie Holland
According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...
According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...
According to long-term follow up...
04/08/2025
Oncology
News
Novel Engineered Toxin Body Targeting CTLA-4 Shows Potential Among Select Advanced Solid Tumors
03/06/2025
Allison Casey
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial,...
03/06/2025
Oncology
News
Promising Efficacy With Bevacizumab Plus Pembrolizumab for Platinum-Resistant Nasopharyngeal Carcinoma
01/23/2025
Stephanie Holland
Results from a phase 2 study found that the addition of bevacizumab to pembrolizumab had superior efficacy to pembrolizumab alone among patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.
Results from a phase 2 study found that the addition of bevacizumab to pembrolizumab had superior efficacy to pembrolizumab alone among patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.
Results from a phase 2 study...
01/23/2025
Oncology
News
First-Line Pembrolizumab Plus Chemotherapy Showed Promise Among Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/26/2024
Stephanie Holland
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the...
07/26/2024
Oncology
Conference Coverage
Addition of Nivolumab to Triple Metronomic Chemotherapy Significantly Improved Overall Survival Among Patients With Advanced Head and Neck Squamous Cell Carcinoma
06/20/2024

Stephanie Holland 

Stephanie Holland 
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose...
06/20/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology

News

News
Sequential Chemoradiotherapy Plus Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
08/19/2025
Stephanie Holland
According to results from a phase 3 trial, sequential chemoradiotherapy plus concurrent chemoradiotherapy was noninferior compared to induction chemoradiotherapy plus concurrent chemoradiotherapy among newly diagnosed patients with...
According to results from a phase 3 trial, sequential chemoradiotherapy plus concurrent chemoradiotherapy was noninferior compared to induction chemoradiotherapy plus concurrent chemoradiotherapy among newly diagnosed patients with...
According to results from a...
08/19/2025
Oncology
Danny Rischin, MD, Peter MacCallum Cancer Centre
Videos
Adjuvant Cemiplimab as New Standard of Care for Patients With High-Risk Cutaneous Squamous Cell Carcinoma
06/06/2025
Danny Rischin, MD
Danny Rischin, MD, discusses the results from the phase 3 C-POST trial evaluating adjuvant cemiplimab for patients with high-risk cutaneous squamous cell carcinoma.
Danny Rischin, MD, discusses the results from the phase 3 C-POST trial evaluating adjuvant cemiplimab for patients with high-risk cutaneous squamous cell carcinoma.
Danny Rischin, MD, discusses the...
06/06/2025
Oncology
Conference Coverage
Adjuvant Nivolumab Plus Chemoradiotherapy Decreases Chance of Recurrence in Patients With Head and Neck Cancer
06/01/2025
Emily Estrada
The addition of nivolumab to cisplatin-based chemoradiotherapy after surgery improved disease-free survival for patients with locoregionally advanced squamous cell carcinoma of the head and neck, according to findings from the NIVOPOSTOP...
The addition of nivolumab to cisplatin-based chemoradiotherapy after surgery improved disease-free survival for patients with locoregionally advanced squamous cell carcinoma of the head and neck, according to findings from the NIVOPOSTOP...
The addition of nivolumab to...
06/01/2025
Oncology
News
Neoadjuvant Nivolumab Plus Chemotherapy and Chemoradiation for Patients With HPV-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma
05/27/2025
Stephanie Holland
According to results from the phase 2 DEPEND trial, neoadjuvant nivolumab plus chemotherapy and response-stratified de-escalated chemoradiation demonstrated promise among patients with HPV-negative locally advanced head and neck squamous cell...
According to results from the phase 2 DEPEND trial, neoadjuvant nivolumab plus chemotherapy and response-stratified de-escalated chemoradiation demonstrated promise among patients with HPV-negative locally advanced head and neck squamous cell...
According to results from the...
05/27/2025
Oncology
News
First-Line Pembrolizumab With or Without Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
04/08/2025
Stephanie Holland
According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...
According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...
According to long-term follow up...
04/08/2025
Oncology
News
Novel Engineered Toxin Body Targeting CTLA-4 Shows Potential Among Select Advanced Solid Tumors
03/06/2025
Allison Casey
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial,...
03/06/2025
Oncology
News
Promising Efficacy With Bevacizumab Plus Pembrolizumab for Platinum-Resistant Nasopharyngeal Carcinoma
01/23/2025
Stephanie Holland
Results from a phase 2 study found that the addition of bevacizumab to pembrolizumab had superior efficacy to pembrolizumab alone among patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.
Results from a phase 2 study found that the addition of bevacizumab to pembrolizumab had superior efficacy to pembrolizumab alone among patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.
Results from a phase 2 study...
01/23/2025
Oncology
News
First-Line Pembrolizumab Plus Chemotherapy Showed Promise Among Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/26/2024
Stephanie Holland
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the...
07/26/2024
Oncology
Conference Coverage
Addition of Nivolumab to Triple Metronomic Chemotherapy Significantly Improved Overall Survival Among Patients With Advanced Head and Neck Squamous Cell Carcinoma
06/20/2024

Stephanie Holland 

Stephanie Holland 
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose...
06/20/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology

Interactive Features

Quiz
Quiz: Docetaxel Plus Radiotherapy For Cisplatin-Ineligible Patients With Head and Neck Carcinoma
09/02/2022
In a study evaluating the addition of docetaxel to radiotherapy for head and neck squamous cell carcinoma, which outcome was improved with docetaxel compared to radiation alone? Test your knowledge with our quiz.
In a study evaluating the addition of docetaxel to radiotherapy for head and neck squamous cell carcinoma, which outcome was improved with docetaxel compared to radiation alone? Test your knowledge with our quiz.
In a study evaluating the...
09/02/2022
Oncology
Test Your Knowledge
Quiz: Single Agent Vs Combo Therapy for Cetuximab in CRC, Head and Neck Cancer
04/22/2021
True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.
True or False: Cetuximab, a novel dosing regimen recently approved by the FDA, can be dosed alone or in combination with chemotherapy for patients with either colorectal or head and neck cancer.
True or False: Cetuximab, a...
04/22/2021
Oncology
Test Your Knowledge
Quiz: Is Lenvatinib a Second-Line Treatment Option for Patients with Thymic Carcinoma?
07/30/2020
True or False: Recent findings suggest that lenvatinib is a potential treatment option for patients with previously treated advanced or metastatic thymic carcinoma.
True or False: Recent findings suggest that lenvatinib is a potential treatment option for patients with previously treated advanced or metastatic thymic carcinoma.
True or False: Recent findings...
07/30/2020
Oncology
Test Your Knowledge
Quiz: Is Age Tied to Disease Progression in Adults With Papillary Thyroid Cancer?
07/13/2020
07/13/2020
Oncology
Test Your Knowledge
Quiz: Late-Line Bemarituzumab Therapy for Advanced Gastroesophageal Cancer
05/22/2020
True or False: Late-line bemarituzumab has been shown to be active and well-tolerated in patients with advanced FGFR2b-overexpressing gastric and GEA.
True or False: Late-line bemarituzumab has been shown to be active and well-tolerated in patients with advanced FGFR2b-overexpressing gastric and GEA.
True or False: Late-line...
05/22/2020
Oncology
Test Your Knowledge
Quiz: Can Acupuncture Prevent Xerostomia in Head and Neck Cancer?
03/02/2020
True or False: Acupuncture may prevent radiation-induced xerostomia in patients with head and neck cancer.
True or False: Acupuncture may prevent radiation-induced xerostomia in patients with head and neck cancer.
True or False: Acupuncture may...
03/02/2020
Oncology
Test Your Knowledge
Quiz: Adding Which Drug to This Combo Therapy Improves Nasopharyngeal Carcinoma Outcomes?
11/08/2019
Adding which drug to cisplatin and chemoradiotherapy improved survival in patients with nasopharyngeal carcinoma?
Adding which drug to cisplatin and chemoradiotherapy improved survival in patients with nasopharyngeal carcinoma?
Adding which drug to cisplatin...
11/08/2019
Oncology
Test Your Knowledge
Quiz: Temozolomide Combo for MGMT-Methylated Glioblastoma
10/01/2019
Which drug plus temozolomide is clinically beneficial for newly diagnosed MGMT-methylated glioblastoma?
Which drug plus temozolomide is clinically beneficial for newly diagnosed MGMT-methylated glioblastoma?
Which drug plus temozolomide is...
10/01/2019
Oncology
Test Your Knowledge
Quiz: Palbociclib and Cetuximab as Therapy for HPV-Unrelated HNSCC
08/29/2019
True or False: Palbociclib and cetuximab therapy has shown promising activity in patients with HPV-unrelated, platinum- or cetuximab-resistant, head and neck squamous-cell carcinomas.
True or False: Palbociclib and cetuximab therapy has shown promising activity in patients with HPV-unrelated, platinum- or cetuximab-resistant, head and neck squamous-cell carcinomas.
True or False: Palbociclib and...
08/29/2019
Oncology
Test Your Knowledge
Quiz: Risk for Brain Metastases Higher With Twice-Daily Radiotherapy for SCLC?
08/01/2019
True or false: Patients with SCLC undergoing radiotherapy twice daily are more likely to have brain metastases after prophylactic cranial irradiation than those given radiotherapy once daily.
True or false: Patients with SCLC undergoing radiotherapy twice daily are more likely to have brain metastases after prophylactic cranial irradiation than those given radiotherapy once daily.
True or false: Patients with...
08/01/2019
Oncology

Recent News

News
Sequential Chemoradiotherapy Plus Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
08/19/2025
Stephanie Holland
According to results from a phase 3 trial, sequential chemoradiotherapy plus concurrent chemoradiotherapy was noninferior compared to induction chemoradiotherapy plus concurrent chemoradiotherapy among newly diagnosed patients with...
According to results from a phase 3 trial, sequential chemoradiotherapy plus concurrent chemoradiotherapy was noninferior compared to induction chemoradiotherapy plus concurrent chemoradiotherapy among newly diagnosed patients with...
According to results from a...
08/19/2025
Oncology
Conference Coverage
Adjuvant Nivolumab Plus Chemoradiotherapy Decreases Chance of Recurrence in Patients With Head and Neck Cancer
06/01/2025
Emily Estrada
The addition of nivolumab to cisplatin-based chemoradiotherapy after surgery improved disease-free survival for patients with locoregionally advanced squamous cell carcinoma of the head and neck, according to findings from the NIVOPOSTOP...
The addition of nivolumab to cisplatin-based chemoradiotherapy after surgery improved disease-free survival for patients with locoregionally advanced squamous cell carcinoma of the head and neck, according to findings from the NIVOPOSTOP...
The addition of nivolumab to...
06/01/2025
Oncology
News
Neoadjuvant Nivolumab Plus Chemotherapy and Chemoradiation for Patients With HPV-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma
05/27/2025
Stephanie Holland
According to results from the phase 2 DEPEND trial, neoadjuvant nivolumab plus chemotherapy and response-stratified de-escalated chemoradiation demonstrated promise among patients with HPV-negative locally advanced head and neck squamous cell...
According to results from the phase 2 DEPEND trial, neoadjuvant nivolumab plus chemotherapy and response-stratified de-escalated chemoradiation demonstrated promise among patients with HPV-negative locally advanced head and neck squamous cell...
According to results from the...
05/27/2025
Oncology
News
First-Line Pembrolizumab With or Without Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
04/08/2025
Stephanie Holland
According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...
According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...
According to long-term follow up...
04/08/2025
Oncology
News
Novel Engineered Toxin Body Targeting CTLA-4 Shows Potential Among Select Advanced Solid Tumors
03/06/2025
Allison Casey
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial, MT-8421, a novel ETB targeting CTLA4, demonstrated acceptable safety with no dose-limited toxicities among patients with select advanced solid tumors.
According to a phase 1 trial,...
03/06/2025
Oncology
News
Promising Efficacy With Bevacizumab Plus Pembrolizumab for Platinum-Resistant Nasopharyngeal Carcinoma
01/23/2025
Stephanie Holland
Results from a phase 2 study found that the addition of bevacizumab to pembrolizumab had superior efficacy to pembrolizumab alone among patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.
Results from a phase 2 study found that the addition of bevacizumab to pembrolizumab had superior efficacy to pembrolizumab alone among patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma.
Results from a phase 2 study...
01/23/2025
Oncology
News
First-Line Pembrolizumab Plus Chemotherapy Showed Promise Among Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
07/26/2024
Stephanie Holland
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the KEYNOTE-B10 trial, first-line pembrolizumab plus carboplatin and paclitaxel showed promising antitumor activity with manageable safety among patients with recurrent or metastatic head and neck squamous cell...
According to results from the...
07/26/2024
Oncology
Conference Coverage
Addition of Nivolumab to Triple Metronomic Chemotherapy Significantly Improved Overall Survival Among Patients With Advanced Head and Neck Squamous Cell Carcinoma
06/20/2024

Stephanie Holland 

Stephanie Holland 
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival among patients with relapsed, recurrent, or newly diagnosed advanced head and neck squamous cell carcinoma.
The addition of low-dose...
06/20/2024
Oncology
News
FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With NRTK Gene Fusion-Positive Solid Tumors
06/14/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase 1/2 TRIDENT-1 study, the US FDA has granted accelerated approval to repotrectinib for adult and pediatric patients 12 years and older with NRTK gene fusion-positive solid tumors.
Based on results from the phase...
06/14/2024
Oncology
Conference Coverage
Tisotumab Vedotin Showed Promising Clinical Activity Among Heavily Pretreated Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
06/11/2024

Stephanie Holland 

Stephanie Holland 
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results...
06/11/2024
Oncology
News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use